نتایج جستجو برای: certolizumab pegol

تعداد نتایج: 885  

2018

[This corrects the article DOI: 10.1136/rmdopen-2017-000582.][This corrects the article DOI: 10.1136/rmdopen-2017-000582.].

2013
D van der Heijde R Fleischmann J Wollenhaupt A Deodhar D Kielar F Woltering C Stach B Hoepken T Arledge P J Mease Tore K Kvien

Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands University of Texas SW Medical Center, Dallas, Texas, USA Schoen Klinik, Hamburg, Germany Division of Arthritis/Rheumatic Diseases (OPO9), Oregon Health & Science University, Portland, Oregon, USA UCB Pharma, Brussels, Belgium UCB Pharma, Monheim am Rhein, Germany UCB Pharma, Raleigh, North Carolina, USA Swedi...

2012
Graeme Jones Erica Darian-Smith Michael Kwok Tania Winzenberg

There have been substantial advances in the treatment of rheumatoid arthritis in recent years. Traditional disease-modifying antirheumatic drugs (DMARDs) have been shown to have small effects on the progression of radiographic damage. This quantitative overview summarizes the evidence for biologic DMARDs and radiographic damage either alone or in combination with methotrexate. Two outcomes were...

Journal: :Digestion 2010
Christoph Reichel Jürgen Streit Karin Ott Steffen Wunsch

BACKGROUND/AIMS The treatment criteria developed by the European Panel on the Appropriateness of Crohn's Disease (CD) Therapy (EPACT) have not been applied to rehabilitation. Thus, we retrospectively evaluated appropriateness of treatments during CD rehabilitation using the EPACT website. METHODS We included our 1-year inpatient rehabilitation patients that had been assigned the International...

2015
Beatrice Bortolato Andre F. Carvalho Joanna K. Soczynska Giulia I. Perini Roger S. McIntyre

Major depressive disorder is a highly prevalent, chronic and recurring disorder, associated with substantial impairment in cognitive and interpersonal functions. Accumulating evidence suggests that inflammatory processes play an important role in the etio-pathogenesis, phenomenology, comorbidity and treatment of MDD. Suboptimal remission rates and the persistence of cognitive deficits contribut...

Journal: :Rheumatology 2012
Michael E Weinblatt Roy Fleischmann Tom W J Huizinga Paul Emery Janet Pope Elena M Massarotti Ronald F van Vollenhoven Jürgen Wollenhaupt Clifton O Bingham Ben Duncan Niti Goel Owen R Davies Maxime Dougados

OBJECTIVE To investigate the efficacy and safety of certolizumab pegol (CZP) in a broad population of patients with active RA. METHODS In this 12-week, double-blind period of the phase IIIb trial, RA patients with inadequate response to at least one DMARD were randomized 4:1 to CZP (400 mg at weeks 0, 2 and 4, followed by 200 mg every 2 weeks) or placebo (every 2 weeks) plus current therapy s...

2017
Tatsuya Atsumi Yoshiya Tanaka Kazuhiko Yamamoto Tsutomu Takeuchi Hisashi Yamanaka Naoki Ishiguro Katsumi Eguchi Akira Watanabe Hideki Origasa Shinsuke Yasuda Yuji Yamanishi Yasuhiko Kita Tsukasa Matsubara Masahiro Iwamoto Toshiharu Shoji Osamu Togo Toshiyuki Okada Désirée van der Heijde Nobuyuki Miyasaka Takao Koike

OBJECTIVES To investigate the clinical impact of 1-year certolizumab pegol (CZP) therapy added to the first year of 2-year methotrexate (MTX) therapy, compared with 2-year therapy with MTX alone. METHODS MTX-naïve patients with early rheumatoid arthritis (RA) with poor prognostic factors were eligible to enter Certolizumab-Optimal Prevention of joint damage for Early RA (C-OPERA), a multicent...

Journal: :Drug discovery today 2015
Axel Vater Sven Klussmann

Spiegelmers are synthetic target-binding oligonucleotides built from non-natural l-nucleotides. Like aptamers, Spiegelmers fold into distinct shapes that bind the targets with high affinity and selectivity. Furthermore, the mirror-image configuration confers plasma stability and immunological passivity. Various Spiegelmers against pharmacologically attractive targets were shown to be efficaciou...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید